Where Particles Are Granulated Patents (Class 424/470)
  • Patent number: 11622938
    Abstract: Described herein are pharmaceutical compositions for the oral administration of nicotinamide, or a combination of nicotinamide and mesalazine, as well as methods of making such pharmaceutical compositions, and therapeutic methods for using them. The compositions comprise delayed-immediate release and delayed-extended release formulation of nicotinamide or a combination of nicotinamide and mesalazine.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: April 11, 2023
    Assignee: CONARIS RESEARCH INSTITUTE AG
    Inventors: Alfred Chi Yeh Liang, Venkataramana Dingari
  • Patent number: 11311570
    Abstract: The invention provides a method of inducing satiety in a subject comprising a step of orally administering a composition comprising an effective amount of a first agent capable of inducing satiety and of a second agent capable of augmenting the satiety-inducing effect of the first agent. Also disclosed are compositions for carrying out the method, and a body weight management system comprising such compositions in combination with a device configured for the collection, storage and/or display of information relating to a subject's response to a predefined therapeutic regimen of orally administering the composition.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: April 26, 2022
    Assignee: PERORA GMBH
    Inventor: Dirk Vetter
  • Patent number: 11000472
    Abstract: The present invention relates to a system for administering a poorly-soluble compound to the skin, the system being capable of exerting an excellent effect by stably impregnating the poorly-soluble compound and effectively delivering the poorly-soluble compound into the skin, and the present invention is technically characterized by a microneedle to which microparticles comprising a poorly-soluble compound are added. In addition, the present invention provides a method for administering a poorly-soluble compound to the skin, the method being characterized by using the microneedle.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: May 11, 2021
    Assignee: LG HOUSEHOLD & HEALTH CARE LTD.
    Inventors: Woo-Sun Shim, Sun-Hwa Lee, Young-Min Hwang, Jung-A Kim, Nae-Gyu Kang
  • Patent number: 10925976
    Abstract: The present invention provides for the incorporation of target sequences of microRNAs into the 3?UTR region of a gene of interest in nucleic acid vectors. The invention also provides for an expression system comprising such vectors, a pharmaceutical composition comprising such vectors, as well as methods of treating or preventing cardiovascular disease by using such vectors.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: February 23, 2021
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Hana Totary-Jain, Andrew Robert Marks, Steven O. Marx
  • Patent number: 10898439
    Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: January 26, 2021
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
  • Patent number: 10874617
    Abstract: Described herein are pharmaceutical compositions for the oral administration of mesalazine, as well as methods of making such pharmaceutical compositions, and therapeutic methods for using them. The compositions comprise delayed-immediate release and delayed-extended release formulation of mesalazine.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: December 29, 2020
    Assignee: FERRING B.V.
    Inventors: Alfred Chi Yeh Liang, Venkataramana Dingari
  • Patent number: 10682338
    Abstract: Method of treating bacterial vaginosis in a subject in need thereof involving administering to the subject a therapeutically effective amount of secnidazole in a microgranule formulation, wherein the microgranule formulation comprises a plurality of microgranules having a volume-weighted particle size distribution within a microgranule population, wherein the volume-weighted particle size distribution as measured from a representative sample of the microgranule population comprises (a) 10% of the microgranule population having a volume-weighted particle size about no less than 470 micrometers; (b) 50% of the microgranule population having a volume-weighted particle size between about no less than 640 micrometers and about no more than 810 micrometers; (c) 90% of the microgranule population having a volume-weighted particle size about no more than 1170 micrometers; or (d) a combination thereof, which can include some or all of (a) through (c) above.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: June 16, 2020
    Assignee: Lupin Inc.
    Inventors: Helen S. Pentikis, David Palling, Carol J. Braun, Richard Holl
  • Patent number: 10639283
    Abstract: A pharmaceutical or nutraceutical composition with a core, an inner layer, and an outercoating layer, wherein a pharmaceutical or a nutraceutical active ingredient is contained in the core, at least 30% by weight of a salt of alginic acid is contained in the inner layer, and at least 30% by weight of a polymer or copolymer with anionic side groups is contained in the outer coating layer.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: May 5, 2020
    Assignee: Evonik Operations GmbH
    Inventors: Priyanka Bansilal Haksar, Shraddha Sanjeev Joshi, Harsh Shah, Preeti Patil, Smitha Shetty
  • Patent number: 10624855
    Abstract: The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: April 21, 2020
    Assignee: Vifor Fresenius Medical Care Renal Pharma Ltd.
    Inventors: Laurent Chofflon, Erik Philipp
  • Patent number: 10568832
    Abstract: There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity in about 60 seconds forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active) applied with a taste-masking membrane comprising a combination of water-insoluble and gastrosoluble polymers release not less than about 60% of the dose is in the stomach in about 30 minutes, thus maximizing the probability of achieving bioequivalence to the reference IR product having rapid onset of action (short Tmax). A process for preparing such compositions for oral administration using conventional fluid-bed equipment and rotary tablet press is also disclosed.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: February 25, 2020
    Assignee: Adare Pharmaceuticals, Inc.
    Inventor: Gopi M. Venkatesh
  • Patent number: 10561612
    Abstract: The invention is directed to a composition comprising cromolyn sodium and ibuprofen, wherein the cromolyn sodium is micronized and the cromolyn sodium and ibuprofen are present in a weight ratio of 1:1-2. In one embodiment, the ibuprofen is passed through a sieve, such as a 300 ?m sieve and to methods of making the same.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: February 18, 2020
    Assignees: The General Hospital Corporation, AZTherapies, Inc.
    Inventors: David R. Elmaleh, Juan B. Gonzalez
  • Patent number: 10471017
    Abstract: There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more task-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active), coated with a taste-masking membrane comprising a water-insoluble polymer and one or more gastrosoluble inorganic or organic pore-formers (practically insoluble in water and saliva, but soluble in an acidic buffer), exhibit acceptable taste-masking when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: November 12, 2019
    Assignee: ADARE PHARMACEUTICALS, INC.
    Inventors: Jin-Wang Lai, Gopi M. Venkatesh, Ken Kangyi Qian
  • Patent number: 10463689
    Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: November 5, 2019
    Assignee: Board of Supervisors of Louisiana State University
    Inventors: Christopher Kevil, Anthony Giordano, Douglas R. Flanagan, Panayiotis P. Constantinides
  • Patent number: 10278925
    Abstract: Compositions for reducing the frequency of urination and methods of manufacture of the compositions are disclosed. One method of manufacture include the steps of forming a first mixture comprising a first active ingredient comprising one or more analgesic, coating the first mixture with a first delayed-release coating to form a first component, forming a second mixture comprising a second active ingredient comprising one or more analgesic agents, coating the second mixture with a second delayed-release coating to form a second component, and combining the first component with the second component to form a third mixture.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: May 7, 2019
    Assignee: WELLESLEY PHARMACEUTICALS, LLC
    Inventor: David A. Dill
  • Patent number: 10076516
    Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: September 18, 2018
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred Tonelli
  • Patent number: 9993433
    Abstract: The present invention relates to prolonged release pharmaceutical dosage forms, the manufacture thereof as well as their use for administration to human beings.
    Type: Grant
    Filed: May 10, 2011
    Date of Patent: June 12, 2018
    Assignee: Euro-Celtique S.A.
    Inventors: Geoffrey Gerard Hayes, Hassan Mohammad, Harjit Tamber, Malcolm Walden
  • Patent number: 9956194
    Abstract: This application relates to pharmaceutical compositions, comprising solabegron that are useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to methods for treating lower urinary tract symptoms utilizing the pharmaceutical compositions, comprising solabegron. In some embodiments, the pharmaceutical compositions, comprising solabegron comprise a dual release drug delivery system.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: May 1, 2018
    Assignee: Velicept Therapeutics, Inc.
    Inventors: Eliot Ohlstein, Raymond E. Stevens, Jr., H. Jeffrey Wilkins
  • Patent number: 9833510
    Abstract: A solid or semi-solid pharmaceutical dosage form comprising non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, along with a second active ingredient having a shorter therapeutically effective plasma concentration duration, such as phenylephrine, and methods of administering the same are provided. This method provides improved therapeutic effect, in particular pain relief along with decongestant relief, over extended time periods.
    Type: Grant
    Filed: June 12, 2007
    Date of Patent: December 5, 2017
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Der-Yang Lee, Robert Shen, Jen-Chi Chen, Vincent Chen
  • Patent number: 9820824
    Abstract: A method for treating a site within a patient from which tissue has been removed includes providing at least one press-formed marker body formed of polysaccharide and a suitable binder; and placing the at least one of the press-formed marker body within the site where tissue has been removed so as to provide hemostasis therein.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: November 21, 2017
    Assignee: SenoRx, Inc.
    Inventors: Michael L. Jones, Paul Lubock
  • Patent number: 9642811
    Abstract: An abuse deterrent immediate release biphasic matrix solid dosage form that releases the drug at a desired rate for quick onset of action when a single unit or prescribed units of the dosage form are orally administered but exhibits a reduced rate of release when more than the prescribed number of units, are administered.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: May 9, 2017
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Nitin Bhalachandra Dharmadhikari, Yashoraj Rupsinh Zala, Dilip Shanghvi
  • Patent number: 9308164
    Abstract: A pharmaceutical dosage form which comprises two or more different hyoscyamine formulations, at least one of the formulations being an immediate release hyoscyamine formulation and at least one other one being a controlled release hyoscyamine formulation. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: April 12, 2016
    Assignee: Sovereign Pharmaceuticals, LLC
    Inventors: Viswanathan Srinivasan, Ralph Brown, David Brown, Himanshu Patel, Juan Carlos Menendez, Somphet Peter Suphasawud
  • Patent number: 9283211
    Abstract: The disclosure teaches counter-intuitive methods for treating stomatitis using oral mTOR inhibiting preparations such as preparations of microcapsules and nanoparticles including an inhibitor of the mammalian target of rapamycin. The methods, preparations and other teachings are useful in various respects, especially for assisting in the treatment, prevention and management of stomatitis in feline subjects and, most especially, the treatment and management of Feline Chronic Gingivo-Stomatitis (FCGS), with secondary applications also related to management of gingivitis and autoimmune mucosal disorders. Disclosed embodiments illustrate multi-week dosing regimens and also address needs for alternative preparations or manufacturing processes that ensure efficacy while improving other performance characteristics such as storage stability, biodistribution, dosage cost, etc.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: March 15, 2016
    Assignee: Rapamycin Holdings, LLC
    Inventor: Dana M Vaughn
  • Patent number: 9095594
    Abstract: Pharmaceutical compositions and methods for treating or preventing bacterial infections are disclosed. The pharmaceutical compositions typically comprise pharmaceutically effective amount of: (a) at least one beta-lactam antibiotic or a pharmaceutically acceptable salt thereof, (b) sulbactam or a pharmaceutically acceptable salt thereof, and (c) at least one beta-lactamase inhibitor or a pharmaceutically acceptable salt thereof, with the provision that the beta-lactamase inhibitor is not sulbactam.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: August 4, 2015
    Assignee: Wockhardt Ltd.
    Inventors: Sachin Subhash Bhagwat, Mahesh Vithalbhai Patel
  • Patent number: 9089607
    Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: July 28, 2015
    Assignee: Impax Laboratories, Inc.
    Inventors: Ann Hsu, Jim H. Kou, Laman Lynn Alani
  • Patent number: 9089608
    Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: July 28, 2015
    Assignee: Impax Laboratories, Inc.
    Inventors: Ann Hsu, Jim H. Kou, Laman Lynn Alani
  • Patent number: 9050263
    Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: June 9, 2015
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
  • Publication number: 20150064251
    Abstract: A tamper-resistant dosage form including a therapeutic agent-substrate complex embedded in a thermo-formable matrix; such that the complex includes at least one therapeutic agent bound to at least one substrate to form the therapeutic agent-substrate complex. The at least one substrate is being selected from the group consisting of a polyelectrolyte, an organic counter-ion, a pharmacologically inert organic component of a prodrug, an inclusion compound and an inorganic adsorbent; and the thermo-formable matrix includes one or more thermoplastic polymers and optionally at least one pharmaceutical additive.
    Type: Application
    Filed: July 3, 2014
    Publication date: March 5, 2015
    Inventor: Isaac Ghebre-Sellassie
  • Publication number: 20150064250
    Abstract: The invention provides a tamper-resistant dosage form including a therapeutic agent-substrate complex embedded in a thermo-formable matrix; such that the complex includes at least one therapeutic agent bound to at least one substrate to form the therapeutic agent-substrate complex. The at least one substrate is being selected from the group consisting of a polyelectrolyte, an organic counter-ion, a pharmacologically inert organic component of a prodrug, an inclusion compound and an inorganic adsorbent; and the thermo-formable matrix includes one or more thermoplastic polymers and optionally at least one pharmaceutical additive.
    Type: Application
    Filed: January 17, 2014
    Publication date: March 5, 2015
    Applicant: ExxPharma Therapeutics LLC
    Inventors: Isaac Ghebre-Sellassie, Hibreniguss Terefe
  • Patent number: 8962022
    Abstract: The present invention is directed to compositions of taste-masked microparticles comprising a substituted benzhydrylpiperazine coated and a taste-masking layer comprising a water-insoluble polymer and a gastrosoluble polymer, and methods of making such taste-masked microparticles. The present invention is also directed to stable orally disintegrating compositions comprising taste-masked microparticles of a substituted benzhydrylpiperazine and rapidly dispersing granules, and methods of making such orally disintegrating compositions.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: February 24, 2015
    Assignee: Aptalis Pharmatech, Inc.
    Inventor: Gopi Venkatesh
  • Patent number: 8956650
    Abstract: An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 ?m, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: February 17, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Motohiro Ohta, Eiji Hayakawa, Kunio Ito, Sanji Tokuno, Kiyoshi Morimoto, Yasushi Watanabe
  • Patent number: 8945618
    Abstract: An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 ?m, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 3, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Motohiro Ohta, Eiji Hayakawa, Kunio Ito, Sanji Tokuno, Kiyoshi Morimoto, Yasushi Watanabe
  • Patent number: 8927014
    Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a superabsorbent material. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material creates a hard gel that traps the microparticles. The hard gel and microparticles provide controlled release of the pharmaceutically active agent.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: January 6, 2015
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Ali Bichara
  • Patent number: 8927017
    Abstract: A method for preparing a gabapentin granulate comprising melt granulating gabapentin with polyethylene glycol having a melting point comprised between 50 and 80° C.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: January 6, 2015
    Assignee: ZAMBON S.p.A.
    Inventors: Luca Rampoldi, Alessandro Grassano
  • Patent number: 8927013
    Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a pharmaceutically active agent that can be the same or different from the pharmaceutically active agent in the microparticles. The composition further comprises a superabsorbent material disposed within the first layer, the second layer, or both the first layer and the second layer. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the composition.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: January 6, 2015
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Ali Bichara
  • Patent number: 8920834
    Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a first layer and a second layer. The core comprises a superabsorbent material (for example, polycarbophil), and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to create a hard gel that traps the microparticles. The hard gel and microparticles provide controlled release of the pharmaceutically active agent. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: December 30, 2014
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Angela Ferrada, Fouzia Soulhi, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Bobby-Ernst Boursiquot, Ali Bichara
  • Patent number: 8920833
    Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the coreswells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: December 30, 2014
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Angela Ferrada, Fouzia Soulhi, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Bobby-Ernst Boursiquot, Ali Bichara
  • Patent number: 8911781
    Abstract: A novel patient-convenient, cost effective pharmaceutical composition, comprising of thiazolidinediones and biguanide for controlling hyperglycemia manufactured as multilayer tablet and its process of manufacturing, for immediate release of thiazolidinediones or thiazolidinediones and biguanide and prolonged release of the biguanide only, the tablet comprising of minimum two layers wherein one outer layer comprises of a mixture of excipients and thiazolidinediones or thiazolidinediones and biguanide allowing immediate release of thiazolidinediones or thiazolidinediones and biguanide respectively and the other layer arranged in contact with the immediate release layer which comprises of a novel composition of excipients and a minimum one or more non-biodegradable, inert polymer(s) and the biguanide allowing pH independent prolonged release of the biguanide up to a period of 8-12 hours. The tablets are for once a day dosing.
    Type: Grant
    Filed: October 14, 2002
    Date of Patent: December 16, 2014
    Assignee: Inventia Healthcare Private Limited
    Inventors: Amit Krishna Antarkar, Rajendra Ghanshamlal Lala, Nirav Mahendra Kamdar, Parag Narayan Gadkari, Maya Janak Shah, Janak Ramanlal Shah
  • Patent number: 8877241
    Abstract: A composition for controlled release of an opioid from a pharmaceutical composition, the method comprises controlling the release of at least one opioid into an aqueous medium by erosion of at least one surface of a pharmaceutical composition comprising I) a matrix composition comprising a) polymer or a mixture of polymers, b) an opioid and, optionally, c) one or more pharmaceutically acceptable excipients, and (i) a coating. The matrix composition has a conus-like shape so the surface area exposed to the aqueous medium increases at least during initial erosion of the matrix composition, and the dissolution of the opioid—when tested in a Dissolution Test as described herein with or without application of sinkers-results in a zero order release of at least 80% of the opioid contained in the composition. Such compositions are especially suitable for controlled release of an opioid to obtain a delayed peak concentration and a prolonged therapeutically effective plasma concentration upon oral administration.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: November 4, 2014
    Assignee: Egalet Ltd.
    Inventors: Gina Fischer, Daneil Bar-Shalom, Lillian Slot, Christine Andersen
  • Patent number: 8877249
    Abstract: A dosage form for controlled release is produced from a composition comprising a granular material having a mean particle diameter of 150 to 350 micrometers and a compactibility resulting in a compact with a tensile strength of at least 1.7 MPa when the granular material is subjected to a compaction pressure of 266 MPa, at least 80 percent of the granular material being a water-soluble cellulose ether, water-soluble cellulose ester, an alkylene oxide homo- or copolymer, or a blend thereof; and an active ingredient.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: November 4, 2014
    Assignee: Dow Global Technologies LLC
    Inventors: Tim D. Cabelka, Akshay Bellare, Ka Chun A. Chan, Tina P. Dasbach, Kacee B. Ender, Karl V. Jacob, Robert E. Scheid, Jr.
  • Patent number: 8877238
    Abstract: Film-coated tablet, consisting of a tablet core with a film coating, or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound, preferably imatinib or a pharmaceutically acceptable salt of imatinib, preferably imatinib monomethanesulfonate, wherein (i) the tablet cores and the granules have been produced by pressing of the starting materials and, prior to pressing of the starting materials, at least one of them has been dry-granulated, preferably compacted; (ii) the tablet cores and granule cores contain the active ingredient in a proportion of 25% by weight to 80% by weight, based on the total weight of the tablet cores or granule cores, together with (iii) at least one filler-binder, and optionally contain other additives; and (iv) the mean particle size distribution of at least 80% of the active ingredient is in the range from 0.01 mm to 1.0 mm.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: November 4, 2014
    Assignee: Siegfried International AG
    Inventors: Lambert Tillmann Röhrich, Beat W. Müller
  • Patent number: 8865219
    Abstract: The invention concerns coated granules including (A) at least one amine-containing pharmacological active principle, preferably as an acid addition salt, the pharmacological active principle being complexed by low cation-exchange resin containing carboxylic acid groups (COO?), and (B) at least 15 wt. %, based on the total weight of the active principle/low cation-exchange resin complex, of at least one hydrophilic adsorbent, the mixture of the components (A) and (B) being coated with a gastrosoluble polymer. The invention also concerns a method for preparing such granules, as well as orodispesible tablets containing such granules.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: October 21, 2014
    Assignee: Ethypharm
    Inventors: Mahendra B. Chaudhari, Edouard Gendrot
  • Patent number: 8846084
    Abstract: The present invention relates to controlled release compositions of Zolpidem or pharmaceutically acceptable salts thereof adapted to release Zolpidem over a predetermined time period, according to a monophasic and/or a biphasic profile of dissolution. The present invention also relates to monolithic matrix based formulations of Zolpidem or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: September 30, 2014
    Assignee: Wockhardt Ltd
    Inventors: Prashant Manohar Mandaogade, Venkatesh Madhavacharya Joshi, Girish Kumar Jain
  • Patent number: 8846085
    Abstract: A directly tabletable ibuprofen formulation comprising a) 50-99% by weight of crystalline ibuprofen, b) 1-15% by weight of a finely divided excipient with a surface area of at least 100 m2/g, and c) 0-40% by weight of further excipients, with the proviso that the total amount of components a) to c) corresponds to 100% by weight, where at least 50% of the surface of the ibuprofen crystals are covered with the finely divided excipient.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: September 30, 2014
    Assignee: BASF SE
    Inventors: Kathrin Meyer-Boehm, Karl Kolter, Anisul Quadir
  • Patent number: 8747896
    Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: June 10, 2014
    Assignee: BioAlliance Pharma
    Inventors: Dominique Costantini, Caroline Lemarchand
  • Patent number: 8722133
    Abstract: The present invention herein provides an imidafenacin-containing orally rapidly disintegrating tablet which is excellent in the photostability. The present invention comprises the steps of: (A) granulating imidafenacin together with starch to thus give a granulated product having an imidafenacin concentration ranging from 0.001 to 3% by mass and a starch concentration ranging from 40 to 99.999% by mass; (B) covering the granulated product prepared in the step (A) with a non-cellulosic coating agent; and (C) blending the granulated product obtained in the preceding step (B) with an excipient and a disintegrating agent and then forming the resulting mixture into a tablet according to the compression molding technique.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: May 13, 2014
    Assignee: Kyorin Pharmaceutical Co., Ltd.
    Inventors: Toshihiro Ishizaki, Yoshinobu Aoki
  • Patent number: 8722083
    Abstract: Various fenofibrate compositions include a plurality of first granules having a high bioavailability in vivo, and a plurality of second granules having a low bioavailability in vivo. The first granules may comprise fenofibrate, from 0.3% to 10% by weight of the first granules of a first surfactant, and a first water soluble or water dispersible cellulose derivative, and the second granules may comprise fenofibrate, from 0% to 0.25% by weight of the second granules of a second surfactant, and a second water soluble or water dispersible cellulose derivative.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: May 13, 2014
    Assignee: Mylan, Inc.
    Inventors: Sarat C. Chattaraj, Glenn Allen Redelman, Andrew Alan Shaw
  • Patent number: 8703191
    Abstract: Controlled-release tablets exhibiting excellent storage stability are achieved by granulating a pharmaceutically active agent with a hydroxyalkylcelluose, blending the resulting granules with an extragranular phase composed of a particulate material that provides a sustained-release matrix, and compressing the blend into a tablet form, which may be optionally coated, such as with an enteric coating composition, to provide delayed release and/or to enhance stability of the active agent.
    Type: Grant
    Filed: July 25, 2007
    Date of Patent: April 22, 2014
    Assignee: Intelgenx Corp.
    Inventors: Horst G. Zerbe, Nadine Paiement
  • Patent number: 8691270
    Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: April 8, 2014
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Angela Ferrada, Fouzia Soulhi, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Bobby-Ernst Boursiquot, Ali Bichara
  • Patent number: 8691272
    Abstract: A multilayer oral dosage form that provides controlled release of an active compound includes a non-erodible core containing a pharmaceutically active compound and/or a nutritionally active compound, and at least one release-modulating layer laminated to each side of the core layer. The dosage form can be prepared using simple, inexpensive tablet compression techniques.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: April 8, 2014
    Assignee: Intelgenx Corp.
    Inventors: Horst G. Zerbe, Nadine Paiement, Pompilia Lspas-Szabo
  • Patent number: 8685447
    Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a pharmaceutically active agent that can be the same or different from the pharmaceutically active agent in the microparticles. The composition further comprises a superabsorbent material disposed within the first layer, the second layer, or both the first layer and the second layer. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the composition.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: April 1, 2014
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Ali Bichara